Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients

Tommaso Di Maira, Angel Rubin, Lorena Puchades, Victoria Aguilera, Carmen Vinaixa, Maria Garcia, Nicola De Maria, Erica Villa, Rafael Lopez‐Andujar, Fernando San Juan, Eva Montalva, Judith Perez, Martin Prieto, Marina Berenguer – 30 March 2015 – Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included.

Liver‐targeted gene therapy: Approaches and challenges

Rajagopal N. Aravalli, John D. Belcher, Clifford J. Steer – 30 March 2015 – The liver plays a major role in many inherited and acquired genetic disorders. It is also the site for the treatment of certain inborn errors of metabolism that do not directly cause injury to the liver. The advancement of nucleic acid–based therapies for liver maladies has been severely limited because of the myriad untoward side effects and methodological limitations.

Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins

Sharon E. Hopcraft, Matthew J. Evans – 29 March 2015 – Hepatitis C virus (HCV) cell entry is a complex, multistep process requiring numerous host cell factors, including the tight junction protein claudin‐1 (CLDN1). It is not known whether CLDN1 and the HCV glycoproteins physically interact. Therefore, the focus of this work was to study genetic interactions between CLDN1 and HCV. We used CRISPR technology to generate CLDN1 knockout (KO) Huh‐7.5 cells, which could not be infected by genotype 2a Jc1 HCV unless CLDN1 expression was restored.

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients

Marta Milano, Alessio Aghemo, Rosellina Margherita Mancina, Janett Fischer, Paola Dongiovanni, Stella De Nicola, Anna Ludovica Fracanzani, Roberta D'Ambrosio, Marco Maggioni, Raffaele De Francesco, Silvia Fargion, Thomas Berg, Felix Stickel, Jochen Hampe, Stefano Romeo, Massimo Colombo, Luca Valenti – 29 March 2015 – Steatosis and inherited host factors influence liver damage progression in chronic hepatitis C (CHC). The transmembrane 6 superfamily member 2 (TM6SF2) gene E167K variant increases liver fat and risk of progressive steatohepatitis by interfering with lipoprotein secretion.

Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy

Jasmohan S. Bajaj, Naga S. Betrapally, Phillip B. Hylemon, Douglas M. Heuman, Kalyani Daita, Melanie B. White, Ariel Unser, Leroy R. Thacker, Arun J. Sanyal, Dae Joong Kang, Masoumeh Sikaroodi, Patrick M Gillevet – 29 March 2015 – Altered gut microbiome is associated with systemic inflammation and cirrhosis decompensation. However, the correlation of the oral microbiome with inflammation in cirrhosis is unclear. Our aim was to evaluate the oral microbiome in cirrhosis and compare with stool microbiome.

MicroRNA‐494 is a master epigenetic regulator of multiple invasion‐suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors

Kuang‐Hsiang Chuang, Christa L. Whitney‐Miller, Chin‐Yi Chu, Zhongren Zhou, M. Katherine Dokus, Shannon Schmit, Christopher T. Barry – 29 March 2015 – Vascular invasion provides a direct route for tumor metastasis. The degree to which microRNA (miRNA) expression plays a role in tumor vascular invasion is unclear. Here, we report that miR‐494 is up‐regulated in human hepatocellular carcinoma (HCC) tumors with vascular invasion and can promote HCC cell invasiveness by gene inactivation of multiple invasion‐suppressor miRNAs.

Reply

Karim J. Halazun, Rachel E. Patzer, Abbas A. Rana, Benjamin Samstein, Robert S. Brown, Jean C. Emond – 29 March 2015

Subscribe to